Skip to main content
Tanvex logo

Tanvex — Investor Relations & Filings

Ticker · 6541 ISIN · KYG8676P1037 TW Manufacturing
Open in API
Filings indexed 26 across all filing types
Latest filing 2026-04-22 Notice of Dividend Amou…
Country TW Taiwan
Listing TW 6541

About Tanvex

www.tanvex.com

Tanvex BioPharma, Inc. specializes in the research, development, manufacturing, and commercialization of biosimilars and innovative biologics. The company operates a vertically integrated model encompassing cell line development, process optimization, and clinical to commercial-scale production. Its portfolio focuses on biosimilars for oncology and supportive care, alongside emerging Antibody-Drug Conjugate (ADC) programs. Tanvex provides comprehensive Contract Development and Manufacturing Organization (CDMO) services, offering a unified platform that supports early-stage development through to commercial manufacturing. By maintaining GMP-compliant facilities and achieving regulatory approval for its biosimilar products, the company delivers end-to-end solutions aimed at increasing the accessibility of safe and effective treatments in international markets.

Recent filings

Filing Released Lang Actions
代重要子公司台灣泰福生技股份有限公司公告 董事會決議不發放股利
Notice of Dividend Amount Classification · 85% confidence The text is a short regulatory disclosure on Taiwan’s public info platform (“公開資訊觀測站”) in which the board of directors resolved not to distribute any dividends. This is a live announcement of dividend decisions by the board, matching the “Notice of Dividend Amount” category (Code: DIV), which covers announcements of dividend amounts or the decision not to pay.
2026-04-22 Chinese
公告本公司董事會決議召開115年股東常會(增列議案)
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal announcement by the board (董事會決議) convening the upcoming Annual General Meeting (股東常會) with full agenda (“召集事由”) including report, approval, discussion, election, and other items. It provides shareholders with the information needed to vote at the meeting, matching the definition of a Proxy Solicitation & Information Statement rather than a presentation or financial report. Therefore, it is classified as PSI (Proxy Solicitation & Information Statement).
2026-04-22 Chinese
依「公開發行公司資金貸與及背書保證處理準則」 第二十五條第一項第四款公告申報
Regulatory Filings Classification · 85% confidence The document is a statutory disclosure under the Taiwan “Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies,” reporting a guarantee provided to a subsidiary. It is not an earnings release, management discussion, annual or interim report, capital financing notice, share issue, dividend notice, or any other specified category. It is a regulatory filing disclosure that does not fit a more specific category, making it a fallback “Regulatory Filings” (RNS).
2026-04-22 Chinese
公告本公司董事會決議私募方式辦理現金增資發行普通股及/ 或私募國內或海外無擔保可轉換公司債案
Share Issue/Capital Change Classification · 85% confidence The document is an official announcement by a listed company (6541 泰福-KY) disclosing a board resolution to conduct a private placement for a cash capital increase via issuance of common shares and/or unsecured convertible bonds. This constitutes a change in the companys capital structure through new share issuance and convertible debt. It is not a full annual or interim report, nor a regulatory notice of a report; rather, it is a direct capital change announcement. Therefore, it fits the Share Issue/Capital Change category (Code: SHA).
2026-04-22 Chinese
公告本公司董事會決議私募方式辦理現金增資發行普通股及/ 或私募國內或海外無擔保可轉換公司債案
Share Issue/Capital Change Classification · 95% confidence The document is a board announcement detailing a private placement of common shares and/or unsecured convertible bonds, including board resolution date, target investors, share amounts, pricing mechanism, and other issuance terms. This is clearly an announcement of a new share issue/capital change. It is not merely a notice of publication or a summary, but the actual capital restructuring proposal. Therefore, it fits the Share Issue/Capital Change category (Code: SHA).
2026-04-22 Chinese
115年3月背書保證與資金貸與
Regulatory Filings Classification · 85% confidence The document is a short regulatory disclosure from the Taiwanese "公開資訊觀測站" showing tables of inter‐company fund loans and guarantees for a single month (March, ROC Year 115) with all zero balances. It does not present full financial statements (not an Annual or Interim Report), nor is it a dividends, management change, or capital transaction announcement. It is a routine mandatory regulatory filing that discloses related‐party financing/guarantee information. Therefore it falls under the general Regulatory Filings category (RNS).
2026-04-09 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.